RUNX2 and acute myeloid leukemia: Jiang et al. found that PRI-724 (a prodrug of C-82 and analog of ICG-001), a second-generation selective antagonist of CBP/β-catenin, promotes apoptosis, inhibits cell growth, and downregulates β-catenin target genes in AML cell lines (MOLM13 and OCI-AML3) as well as in stem/progenitor cells.